DESIGN AND OBJECTIVES: Potential risk factors for recurrence of tuberculosi
s (TB) were investigated in a retrospective cohort study of 305 human immun
odeficiency virus (HIV) positive and 984 HIV-negative South African gold mi
ners treated for TB with directly-observed, rifampicin-based regimens. Stan
dard treatment changed from rifampicin, isoniazid and pyrazinamide (RHZ) to
RHZ plus ethambutol (RHZE) during the study period.
RESULTS: Recurrence occurred in 37 HIV-positive and 46 HIV-negative men. HI
V infection was associated with a significantly higher recurrence rate (8.2
vs 2.2 per 100 person-years; multivariate-adjusted incidence rate ratio [I
RR] 4.9, 95% confidence interval [CI] 3.0-8.1), as were post-tuberculous sc
arring (multivariate-adjusted IRR 1.6 for one or two scarred lung zones, 4.
0 for three or more zones; test for trend P < 0.001) and drug resistance (m
ultivariate-adjusted IRR 2.7, 95%CI 1.01-7.4). The recurrence rate was sign
ificantly higher following treatment with RHZ than RHZE (multivariate-adjus
ted IRR 2.1, 95%CI 1.1-4.0). The difference between regimens needs to be in
terpreted with caution, however, as allocation was not randomised.
CONCLUSION: The high recurrence rate among HIV-positive men requires furthe
r investigation to distinguish relapse from re-infection as the predominant
cause, leading to consideration of further intensification of the initial
regimen or use of secondary prophylaxis.